BioLife Solutions Financials
| BLFS Stock | USD 22.75 0.09 0.39% |
Operating Margin | Profit Margin | Short Ratio 7.48 | EPS Estimate Current Year 0.02 | EPS Estimate Current Quarter (0.04) |
Investors should never underestimate BioLife Solutions' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor BioLife Solutions' cash flow, debt, and profitability to make informed and accurate decisions about investing in BioLife Solutions.
Net Income |
|
BioLife | Select Account or Indicator | Build AI portfolio with BioLife Stock |
Understanding current and past BioLife Solutions Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BioLife Solutions' financial statements are interrelated, with each one affecting the others. For example, an increase in BioLife Solutions' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in BioLife Solutions' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioLife Solutions. Check BioLife Solutions' Beneish M Score to see the likelihood of BioLife Solutions' management manipulating its earnings.
BioLife Solutions Stock Summary
BioLife Solutions competes with JetBlue Airways, Canlan Ice, Copa Holdings, United Parks, and Singapore Airlines. BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington. Biolife Solutions operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 432 people.Specialization | Health Care, Health Care Equipment & Services |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US09062W2044 |
| CUSIP | 09062W204 229049101 09062W105 |
| Location | Washington; U.S.A |
| Business Address | 3303 Monte Villa |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.biolifesolutions.com |
| Phone | 425 402 1400 |
| Currency | USD - US Dollar |
BioLife Solutions Key Financial Ratios
| Revenue | 82.25 M | ||||
| Gross Profit | 57.22 M | ||||
| EBITDA | 1.53 M | ||||
| Net Income | (20.18 M) | ||||
| Total Asset | 399.49 M |
BioLife Solutions Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 234.8M | 552.6M | 450.2M | 412.7M | 399.5M | 419.5M | |
| Other Current Liab | 9.1M | 20.2M | 15.7M | 18.6M | 12.3M | 13.0M | |
| Net Debt | (79.3M) | (43.0M) | 24.3M | 7.3M | (65.2M) | (62.0M) | |
| Retained Earnings | (97.4M) | (105.0M) | (246.9M) | (313.3M) | (335.1M) | (318.3M) | |
| Accounts Payable | 3.7M | 14.9M | 15.4M | 6.9M | 3.6M | 2.1M | |
| Cash | 90.5M | 69.9M | 19.4M | 35.4M | 95.4M | 100.2M | |
| Other Assets | 50K | 120.1M | 426.7M | 386.2M | 444.1M | 466.3M | |
| Other Current Assets | 4.7M | 4.7M | 6.9M | 6.8M | 6.0M | 6.3M | |
| Total Liab | 29.6M | 71.9M | 86.0M | 75.1M | 50.6M | 53.1M | |
| Total Current Assets | 114.7M | 125.9M | 138.5M | 120.6M | 148.8M | 156.2M | |
| Inventory | 11.6M | 28.3M | 34.9M | 43.5M | 29.0M | 30.5M | |
| Net Receivables | 8.0M | 23.2M | 33.9M | 18.7M | 9.2M | 9.6M | |
| Short Term Debt | 1.7M | 6.7M | 7.9M | 10.0M | 12.5M | 13.1M | |
| Common Stock | 33K | 42K | 43K | 45K | 47K | 37.1K | |
| Intangible Assets | 31.0M | 152.1M | 32.1M | 21.1M | 9.6M | 9.1M | |
| Other Liab | 41.1M | 14.0M | 31.9M | 2.6M | 3.0M | 2.8M | |
| Net Tangible Assets | (12.2M) | 205.2M | 480.8M | 364.2M | 418.8M | 439.8M |
BioLife Solutions Key Income Statement Accounts
The reason investors look at the income statement is to determine what BioLife Solutions' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 18K | 485K | 687K | 1.8M | 719K | 755.0K | |
| Total Revenue | 48.1M | 119.2M | 161.8M | 143.3M | 82.3M | 86.4M | |
| Gross Profit | 27.4M | 37.7M | 53.8M | 46.8M | 57.8M | 60.6M | |
| Operating Income | (3.3M) | (30.4M) | (39.9M) | (70.8M) | (7.1M) | (7.5M) | |
| Ebit | (4.7M) | (32.7M) | (43.1M) | (57.5M) | (7.1M) | (7.5M) | |
| Ebitda | 1.1M | (17.8M) | (23.2M) | (45.2M) | 1.5M | 1.6M | |
| Cost Of Revenue | 20.6M | 81.4M | 107.9M | 96.5M | 24.5M | 12.4M | |
| Net Income | 2.7M | (8.4M) | (139.8M) | (66.4M) | (20.2M) | (19.2M) | |
| Income Tax Expense | (3.3M) | (20.3M) | (5.0M) | 169K | (38K) | (39.9K) | |
| Income Before Tax | (597K) | (28.7M) | (144.8M) | (66.3M) | (11.4M) | (12.0M) | |
| Research Development | 6.7M | 11.8M | 14.8M | 18.8M | 7.9M | 8.3M | |
| Net Interest Income | 58K | (432K) | (687K) | (1.7M) | (719K) | (683.1K) | |
| Tax Provision | (3.3M) | (20.3M) | (5.0M) | 127K | (38K) | (39.9K) |
BioLife Solutions Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 84.0M | (20.6M) | (50.4M) | 16.0M | 59.9M | 62.9M | |
| Free Cash Flow | 1.9M | (13.2M) | (18.9M) | (18.9M) | 5.2M | 5.5M | |
| Depreciation | 5.1M | 12.9M | 16.5M | 12.3M | 8.7M | 9.1M | |
| Other Non Cash Items | (2.1M) | (364K) | 109.7M | 8.6M | (11.1M) | (10.6M) | |
| Capital Expenditures | 4.6M | 8.4M | 10.4M | 6.4M | 3.2M | 3.4M | |
| Net Income | 2.7M | (7.6M) | (139.8M) | (66.4M) | (20.2M) | (19.2M) | |
| End Period Cash Flow | 90.5M | 69.9M | 19.5M | 35.4M | 95.4M | 100.2M | |
| Change To Inventory | (629K) | 114K | (6.6M) | (8.6M) | 781K | 820.1K | |
| Change To Netincome | 15.0M | (1.2M) | (9.0M) | 114.8M | 132.0M | 138.6M | |
| Investments | (23.7M) | (12.6M) | (58.1M) | (1.0M) | 58.3M | 61.2M |
BioLife Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioLife Solutions's current stock value. Our valuation model uses many indicators to compare BioLife Solutions value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioLife Solutions competition to find correlations between indicators driving BioLife Solutions's intrinsic value. More Info.BioLife Solutions is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value BioLife Solutions by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.BioLife Solutions Systematic Risk
BioLife Solutions' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BioLife Solutions volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on BioLife Solutions correlated with the market. If Beta is less than 0 BioLife Solutions generally moves in the opposite direction as compared to the market. If BioLife Solutions Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BioLife Solutions is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BioLife Solutions is generally in the same direction as the market. If Beta > 1 BioLife Solutions moves generally in the same direction as, but more than the movement of the benchmark.
BioLife Solutions July 4, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BioLife Solutions help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BioLife Solutions. We use our internally-developed statistical techniques to arrive at the intrinsic value of BioLife Solutions based on widely used predictive technical indicators. In general, we focus on analyzing BioLife Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BioLife Solutions's daily price indicators and compare them against related drivers.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 20.54 | |||
| Value At Risk | (6.95) | |||
| Potential Upside | 7.28 |
Additional Tools for BioLife Stock Analysis
When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.